Drug
Rpl554
Rpl554: highest development phase Phase 2, developed by Merck. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| RPL554 Suspension NCT03673670 | Phase 2 | COPD |
| RPL554 NCT02919995 | Phase 2 | Cystic Fibrosis |
| RPL554 suspension NCT03443414 | Phase 2 | COPD |
| RPL554 NCT02427165 | Phase 2 | Asthma |
| RPL554 NCT02307162 | Phase 1 | Inflammatory Disorder of the Respiratory Tract |
Latest
No recent events.
Follow Rpl554 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.